Global Cell and Gene Therapy CRO Market Research 2024-2035: Over 105 CROs Drive Innovations with 80% Ensuring Comprehensive Support from R&D to Clinical Trials [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering. The global cell and gene therapy CRO market is estimated to grow from $1.65 billion in 2024 to $3.51 billion by 2035, representing a CAGR of 7.1% during the forecast period 2024-2035. The new research study consists of industry trends, detailed cell and gene therapy CRO market analysis, key market insights, market impact analysis, market forecast and opportunity analysis. The rise in the opportunity for contract research organizations over the next decade is likely to be the result of the anticipated rise in the demand for cell and gene therapies. Cell and gene therapy candidates have demonstrated the potential to treat rare and complex diseases, including indications, for which no effective treatment is currently available. It is important to mention that, in case of cell therapy, human ce
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- High Growth Tech Stocks to Watch in September 2024 [Yahoo! Finance]Yahoo! Finance
- High Growth Tech And 2 Other High Potential Stocks To Watch [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society CongressBusiness Wire
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $152.00 price target on the stock.MarketBeat
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $181.00 price target on the stock.MarketBeat
SRPT
Earnings
- 8/7/24 - Beat
SRPT
Sec Filings
- 9/16/24 - Form 4
- 9/16/24 - Form 3
- 9/16/24 - Form 8-K
- SRPT's page on the SEC website